A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus.

The European Task Force unveils critical updates on Guillain-Barré syndrome, highlighting new treatment strategies and diagnostic criteria for clinicians. News & Perspective Tools & Reference CME/CE.

References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.

FRESNO, Calif. (KFSN) -- Turning pain into action. It's been eight years since Rob Vasquez was diagnosed with Guillain-Barré Syndrome. "It's been a long journey," said Cheryl Vasquez, Rob's wife.

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...

Reports of Guillain-Barré syndrome (GBS) following respiratory syncytial virus (RSV) vaccination in adults ages 60 and up were higher than expected, but the vaccine's benefits still outweigh any ...

One day, a local man was happy and healthy, and the next day, he was paralyzed and needed breathing and feeding tubes. That’s how fast Guillain-Barré syndrome can strike.